Introduction
Weight gain is one of the most important side effects associated with antipsychotic treatment. It adversely influences both somatic health (for example, is associated with diabetes, heart diseases and other serious states) and personal well-being of patients, with a reduction in compliance, and the risk of illness recurrence as a possible consequence. The importance of this problem was shown by Fontaine et al., 1 who found that clozapine, although preventing suicide in 492 per 100 000 schizophrenic patients in the 10-year period, at the same time could be considered responsible for 416 deaths because of the consequences of antipsychotic-induced weight gain.
Among atypical neuroleptics, olanzapine and clozapine have been associated with the highest weight gain, with the mean increase in weight at the level of 5 kg during short-term treatment 2 and 6-7 kg during long-term treatment.
play an important role in the regulation of feeding behavior in rodents 5 and humans, 6 in particular through 5-HT2C receptors. It was shown that, compared with wild-type mice, knockout mice lacking this receptor gene were obese due to hyperphagia. 7 Genetic factors are thought to play a role in individual response to antipsychotic drugs-both in terms of benefits from the treatment and in susceptibility to side effects. Variations in gene sequence, called polymorphism, might influence the proprieties of encoded proteins, and result in individual response to drugs. Some polymorphisms were earlier found to be associated with weight gain, for example, polymorphisms in ADRA2A or SNAP-25 genes. 8 However, the strongest association was shown for polymorphisms in the 5-HT2C receptor gene (HTR2C gene), which supports its role suggested by pharmacological studies.
The HTR2C gene is located on the chromosome Xq24 and contains several polymorphisms. Although the results for an association of the first polymorphism studied, Cys23Ser in the coding region, with antipsychotic-induced weight gain were mostly negative, 9, 10 encouraging data were obtained for the polymorphisms in the promoter region of this gene, identified by Yuan et al., 11 namely, À697G/C, À759C/T, À997G/A and (GT)n repeat at À1027 within the 5 0 flanking region. A number of studies investigated the potential role of these polymorphisms in weight gain control. Yuan et al. 11 hypothesized their association with the obesity status, and specifically of À697C, À759T and À995A alleles with leanness. The role of the À759C/T polymorphism was further examined in the context of neuroleptic-induced weight gain. The À759T variant was found to be associated with lower weight gain in drug-naïve and first-episode psychotic patients, [12] [13] [14] multi-episode patients 15 and treatment-resistant patients, 16 although the results have not been completely consistent [17] [18] [19] [20] and a meta-analysis of studies confirmed its role under only one statistical model. 21 Another study suggested the role of this polymorphism in resistance to weight loss. 22 One study showed the role of this single nucleotide polymorphism (SNP) in a haplotype with the Ser allele of the Cys23Ser and the long allele of the (GT)n polymorphisms. 23 The above polymorphisms are of special interest because of their vicinity to the major transcription initiation site in position À703. 24, 25 Indeed, a number of studies have proved their functionality; they were shown to influence transcription rates. This may potentially have an effect on response to drugs; as a decrease in serotonin levels increases feeding, 16 and this action of serotonin is partly mediated through HTR2C receptor, theoretically a reduction in this receptor number/activity might have a similar effect to low serotonin levels. According to this hypothesis, the variants associated with a higher expression might have a protective effect against weight gain. However, on the basis of the available studies, the direction of changes in expression remains unclear. Yuan et al. 11 showed a higher expression of haplotypes containing both À759T and À697C alleles and the À697G allele alone, by 2.58 and 1.44-fold, respectively, when compared with the haplotype containing only wild alleles (À759C and À697G). A higher expression associated with the À759T allele was confirmed by another study, 26 although it did not examine the À697G/C SNP. However, Hill et al. 27 showed a decrease in HTR2C promoter activity when the above alleles were present. Such a decrease in activity in the presence of À697C allele, with a further reduction by the À759C and the À997G alleles, was also found by McCarthy et al. 28 Although the findings are not consistent between the studies, most of them suggested that the role of the À697G/C polymorphism in the regulation of the promoter activity was greater than that of the À759C/T SNP. It is also worth noting that the À759C/T polymorphism seems to be in linkage disequilibrium with the À997G/A SNP. Therefore, the latter one, not the À759C/T, might in fact be the functional one. Yuan et al. 11 showed a complete linkage disequilibrium between the above SNPs forming the À997G/À759C and the À997A/À759T haplotypes. However, Buckland et al. 26 observed that although the À759T allele confers a higher gene activity, this activity is decreased by the À997A variant allele. More studies on functional effects of those polymorphisms are necessary to clarify the influence of the above SNPs. Also, the mechanisms underlying changes in promoter activity are unknown. One of the possibilities might be alterations in the affinity for transcription factors, another-a disruption of the promoter site, especially in case of the À697 SNP. 28 However, this has not been proven yet.
This study aimed to assess whether there is an association between the À697G/C and the À759C/T polymorphisms of the HTR2C gene and olanzapine-induced weight gain. In order to make our study comparable with other studies, we used the criterion of body mass index (BMI) increase X7, X10% and a quantitative analysis with the full range of BMI values (expressed as a % change from baseline values).
Results
As the HTR2C gene is located on the chromosome X, men are hemizygotic (that is, they have only one allele). In this study, 13/53 (24.5%) men had the À759T and 22/53 (41.5%) had the À697C variant alleles. Women presented with all three genotypes for both polymorphisms and the variant alleles were present both in a heterozygotic and a homozygotic form (À759: CT In the analysis, we used an approach on the basis of the presence of the variant alleles thought to be protective against weight gain.
Demographic characteristics of patients according to the presence/absence of variant alleles (À759T, À697C) and haplotypes are shown in Table 1 . We did not observe any significant difference in age, age at onset, pre-olanzapine treatment duration in earlier treated patients, baseline weight, baseline BMI and baseline psychopathology (PANSS scale, Positive and Negative Syndrome Scale) between these genotype variant groups.
By stepwise regression analysis we excluded the influence of sex, age, age at onset and duration of pre-olanzapine antipsychotic treatment on BMI change. Only baseline BMI and baseline total PANSS score had a significant effect on BMI change (P ¼ 0.02 and 0.004, respectively).
Analysis of variance was carried out to assess the influence of the alleles when a full range of BMI values, expressed as a % change from baseline BMI, was used. The only statistically significant effect was shown for the À759C allele, which was associated with a higher BMI increase (P ¼ 0.038, F ¼ 4.41; À759C present: mean 5.89, s.d. 6.25; À759C absent: mean 2.20, s.d. 5.12). However, this association was no longer significant when baseline BMI and baseline total PANSS values were included as cofactors (P ¼ 0.187). The results for other variants and haplotypes were not significant (data not shown).
The analysis (w 2 -tests) using the criteria of 7 and 10% increase in BMI, considered as indicative of clinically significant weight gain in earlier studies, was carried out. Both examined polymorphisms were separately associated with X10% increase in BMI, also when Bonferroni's correction for multiple testing was applied (Po0.001; Tables  2 and 3 ). No patient with the À759T allele experienced a X10% BMI increase, whereas it occurred in 26.6% of the patients without this allele (Table 2) . Also, only 6.0% of the patients in possession of the À697C allele experienced a X10% increase in BMI compared with 32% of the patients without this allele (Table 3) . To exclude the blurring of the results by initial BMI values falling out of normal range, the data were re-analyzed including only 67 patients with the initial BMI within the normal range (18.5-24.9) . Association of genotypes with a X10% BMI increase was confirmed in this subgroup: w 2 ¼ 5.71, P ¼ 0.01 for the possession of the À759T allele and w 2 ¼ 5.97, P ¼ 0.01 for the possession of the À697C allele. Again, the associations remained significant after Bonferroni's correction for multiple allele testing was applied.
Application of the 7% increase in BMI cutoff level did not yield any significant results for any of the examined polymorphisms (P40.05).
Additionally, an analysis for haplotypes of the À697G/C and the À759C/T polymorphisms was carried out. The association of haplotypes with a X10% BMI increase was found (w 2 ¼ 13.03, P ¼ 0.001). The results are presented in Figure 1 . Interestingly, the À759T allele was always accompanied by the À697C allele; however, when the À759T allele was absent, the À697C allele might be either absent or present. The haplotype containing only the À759T allele and lacking the À697C allele was not identified in any of the patients. No patient in possession of both À759T and À697C alleles experienced a BMI increase X10%, whereas it was true for 13% of the patients with only the À697C allele, and 32% of the patients without any of the 'protective' alleles. The association persisted after excluding patients Table 1 Demographic characteristics of the patients according to the presence/absence of the HTR2C gene variant alleles (À759T, À697C) and haplotypes. Data presented as median (minimum-maximum) 
Baseline weight (kg) 
Baseline PANSS 
The presented analyses were carried out using Mann-Whitney U-test for genotypes and Kruskal-Wallis test for haplotypes.
Olanzapine, weight gain and HTR2C gene SNPs The above results were confirmed in the subgroup of 36 drug-naïve first-episode patients, although the significance was lower, and in case of the À759C/T polymorphism we observed threshold values (w 2 ¼ 3.82, P ¼ 0.05 for the À759T allele; w 2 ¼ 6.97, P ¼ 0.008 for the À697C allele; and w 2 ¼ 6.97, P ¼ 0.03 for the haplotypes). In this group no patient possessing either À759T or À697C allele experienced X10% increase in BMI. The association persisted when only patients with a normal initial BMI were included (P ¼ 0.06; 0.01 and 0.04, respectively). However, after Bonferroni's correction for multiple allele testing was applied, only association of À697C allele remained significant in this group.
As baseline total PANSS score and BMI values were found by stepwise regression analysis to have a significant effect on BMI change, the additional log-linear analysis was carried out to rule out their possible influence on the postulated association between the weight gain and the presence of the two alleles. The interval variables-BMI and total PANSS score-were transformed to dichotomic variables. The pretreatment 24.9 value for BMI and 103 total PANSS score (median values for total group) were taken as threshold values. The log-linear analysis was carried out with four design variables: the pretreatment BMI (o or Abbreviation: BMI, body mass index. P values are significant after Bonferroni's correction for multiple testing (Po0.025).
Olanzapine, weight gain and HTR2C gene SNPs BR Godlewska et al X25.0) (variable1) and total PANSS (o or X103) (variable2), the presence/absence of À759T (variable3) and À697C (variable4) allele, and one response variable: the increase in BMI (o 10% orX10%) (variable5) after olanzapine treatment. The automatic model fitting option was used. The model with two interactions: variable4 and variable5, and variable4 and variable3, was necessary and sufficient to describe all the analyzed data (the goodnessof-fit: w 2 ¼ 11.439; df ¼ 25; P ¼ 0.99). The response variable-increase in BMI-showed significant negative association only with one design variable-the presence of the -697C allele.
Interactions of PANSS and BMI were checked using the 10% increase of BMI as a threshold value, according to which patients were divided into two subgroups. The baseline BMI value in the subgroup with treatment-associated BMI increase X10% was lower (21.9±3.4) than in the subgroup with BMI increase o10% (24.2 ± 4.4) (P ¼ 0.055). There was a significant difference (P ¼ 0.03) in baseline total PANSS score-but not in positive, negative and general subscales scores separately-between patients with the BMI increase X10% (95.3 ± 13.8) and those with BMI increase o10% (102.5±19). However, no further significant correlation was observed between BMI increase (both in % and in kg) and % change in PANSS score (total score and positive, negative and general subscales scores) when Spearman's rank coefficient and Mann-Whitney U-test were used to compare the above subgroups.
Discussion
This study reports a protective role of the À759T variant allele of the À759C/T polymorphism (rs3813929) and the À697C variant allele of the À697G/C polymorphism (rs518147) of the HTR2C gene against antipsychotic-induced substantial weight gain defined as X10% increase in BMI. To our knowledge, this was the first study that investigated a role of the À697G/C polymorphism in antipsychotic-induced weight gain. The analysis of haplotypes suggested that the presence of the À697C variant was crucial for the protective effect, and the À759T might have an additive effect.
The HTR2C receptor has recently received attention as a factor possibly influencing weight gain both in the general population and in patients treated with antipsychotic drugs. Currently, a protective role of the À759T allele against weight gain seems to be the most consistent finding. Yuan et al. 11 found a higher frequency of this allele in the nonobese group of individuals without schizophrenia. Pooley et al. 22 found an association of À759C/T heterozygotes with resistance to weight loss in a group of 120 obese women. Reynolds et al. 13 conducted the first study that examined an influence of this polymorphism on weight gain during antipsychotic treatment and found a lower increase in BMI after 6 and 10 weeks of the treatment in drug-naïve patients possessing the À759T allele, with no patient in this group experiencing a BMI increase 47% after 6 weeks. In the first study using olanzapine, an association of the À759T allele with o10% weight gain increase after 6 weeks of the treatment was found in 42 patients with a history of multiple psychotic episodes. 15 In another study, 16 including 41 treatment resistant patients treated with clozapine, a higher frequency of the À759T allele among patients with BMI increase o7% was observed. The protective effect of the À759T allele against BMI increase after 6 weeks, 3 and 9 months of the treatment (greatest at 6 weeks) was also found in a recent study of 73 drug-naïve patients with first psychotic episode.
14 Patients were treated with different antipsychotics, but the results held true for a small subgroup of 19 patients treated with olanzapine. The protective role of this SNP was further supported by Ryu et al. 29 in the Korean population. A recent meta-analysis by DeLuca et al. 21 found a weak support for À759C/T polymorphism role in weight gain under one statistical model. One study showed the role of the haplotype containing this allele, Ser allele of the Cys23Ser and long allele of the (GT)n polymorphisms. 23 However, four other studies failed to show the protective role of the À759T allele: three including 80-97 treatment-resistant patients receiving clozapine, measurements taken after 4 months, 17 6 weeks 18 and 12 weeks, 19 and another study including 79 patients treated with olanzapine for at least 3 months. 20 In one study 13 the protective effect was shown for men, whereas there were only slight differences in BMI in the subgroup of women stratified by genotype. Although our study confirmed the protective role of the À759T allele against weight gain, we cannot confirm sex-dependent differences reported in the above-cited paper (results not presented).
Studies on the À697G/C polymorphism in the context of weight gain are scarce. Yuan et al. 11 found a higher frequency of the À697C (variant) allele in non-obese individuals without schizophrenia.
The only study that examined haplotypes including both above SNPs in the context of obesity was that of Yuan et al.
11
In a group of 586 men they observed an association of haplotypes including both the À759T and the À697C alleles with leanness, those not including any of the 'protective' alleles with obesity and a tendency of the haplotype containing only the À697C allele to prevail in non-obese individuals. Our results are consistent with those findings. In our group we observed a protective effect against antipsychotic-induced weight gain in case of both haplotypes containing À697C allele. The data (Figure 1) suggest that the major factor in this phenomenon might be the presence of the À697C, and not the À759T allele. The presence of the À697C allele seems to be sufficient to protect most of the patients against weight gain. We hypothesize that the role of the À759T allele adds to this effect, as no patient with both À759T and À697C alleles had a substantial BMI increase, and it was true for a small proportion of patients with only À759T allele but lacking the À697C allele. This hypothesis is supported by statistical analysis showing a stronger association of 10% BMI increase with the presence of the À697C allele (Table 3) than the À759T allele (Table 2) . Moreover, the significance attributed to the presence of the À759T allele when the alleles were analyzed separately (Table 2 ) may be in fact a result of including patients with both 'protective' alleles into the group, in which À697C might have a primary effect. The results of log-linear analysis support this hypothesis. However, the number of patients included into the study is too small to draw more definite conclusions. In order to estimate the influence of À759T allele itself it would be helpful to analyze the haplotype in which the À759T allele would be present and the À697C allele-absent. Unfortunately, this haplotype was not identified in the examined group, nor was it present in the large group analyzed by Yuan et al., 11 which suggests it might be rare.
Although the results obtained with analysis of variance, showing a higher BMI increase in case of the À759C allele presence, are not directly supportive of the above effect, neither are they contradictory to it, as the À759C allele may play the opposite role to the À759T allele according to the functionality studies, discussed in greater detail in the introduction.
The findings in our first-episode drug-naïve patients were similar to those in the entire group. No patients in possession of any of the variant alleles suffered from X10% weight gain versus 44% of patients possessing none of them. Again, the group was too small to draw more definite conclusions but it is possible that the effect of the variants, especially of the À697C allele, in drug-naïve patients might be stronger than in the group earlier treated with other drugs.
It is worth noting that for the whole group, as well as for a subgroup of drug-naïve patients, a proposed criterion of 7% BMI increase was inadequate and the difference became significant only when the threshold was increased to 10%. The same threshold as the only significant was also found in another study. 15 Although the results of most studies, including ours, seem to point at the role of the above polymorphisms in antipsychotic treatment weight gain, all of them suffer from major problems that have to be taken into account, and which may be, at least in part, responsible for the discrepancies in results. Usually only small numbers of patients-very often o50-were included, which makes the statistical analysis prone to errors. Moreover, the type of patients included was highly variable between the studies, ranging from drug-naïve first-episode to treatment resistant chronic patients; those groups could react differently to drugs. Also, the studies varied in terms of the drugs used, with drugs of different propensities of causing weight gain being used. This raises the question of the comparability of the results.
Unfortunately, our study, as others, is not free from drawbacks. Although the study included the highest so far number of patients treated with one antipsychotic drug in monotherapy, it still suffers from limited group size, which limits the power. Thus the results, although promisingly consistent with the earlier findings, have to be considered tentative. Additionally, it was impossible to assess the exact caloric intake, which could differ as patients were allowed to get additional food, such as sweets, from their families. However, the level of activity and the caloric input from the hospital diet did not differ substantially between patients. Another critical issue is compliance to treatment. 30 It was improved by including only inpatients into the study and by a strict collaboration between patients and the personnel (for example, psychoeducation was supplied to all patients). However, olanzapine plasma levels would be a useful indicator of compliance and should be considered in further studies.
In summary, our study not only supports the importance of the À759T variant allele of the HTR2C gene in protection against antipsychotic-induced weight gain, but also suggests the role of another polymorphism of this gene, the À697G/ C, in this phenomenon. We hypothesized that the À697C allele may in fact have a bigger effect in protection against weight gain and that the role of À759T allele is additive or secondary. This study was one of the few that used olanzapine, and included the highest number of patients so far treated with one drug, especially with such high potential of inducing weight gain. 2, 3, 31 The additional strength of the study is an inclusion of a small group of first-episode drug-naïve patients, in whom the results were confirmed. However, because of the shortcomings discussed above, more studies are necessary to establish more definitively the role of HTR2C gene polymorphisms in the phenomenon of weight gain after treatment with antipsychotic drugs.
Materials and methods
The study included 107 participants (mean age 29.3 ± 10.0) with the diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IVTR) criteria: 103 with paranoid and 4 with undifferentiated subtypes; 54 women (mean age 32.2±11.8 years) and 53 men (mean age 26.3±6.7 years). All patients were of Caucasian race, of Polish origin; they were recruited and assessed in Lublin, and molecular analysis was carried out in Gdansk. The diagnosis was set by experienced psychiatrists, who underwent training in diagnosis setting according to the DSM-IVTR criteria, PANSS assessment and standardization of measurements. Exclusion criteria from the study were: comorbid mental disorder, addiction or somatic illness; concomitant treatment with other antipsychotic or antidepressant drugs or mood stabilizers; earlier use of atypical antipsychotics, including olanzapine or clozapine associated with the highest weight gain; resistance to earlier drug treatment. All participants were inpatients, put on the same hospital diet, although the exact caloric input was not measured and patients were not controlled for an additional intake of sweets and so on. Exercise level was comparable for most of the patients, as most them at the initial phase of psychosis stayed in hospital. All patients were on olanzapine monotherapy in a dose range 20-25 mg per day. Benzodiazepine use was permitted in the first and second week of the treatment. Eleven patients were occasionally given lorazepam in a dose up to 5 mg per day (five patients once, three-twice and three-three times). No other drugs were permitted. Among 107 patients, 71 suffered from multiple episodes in the past and were earlier treated with various typical drugs. None of those patients was earlier treated with atypical antipsychotics. No patient was treatment resistant to typical drugs (switch to olanzapine was mainly due to side effects, for example, extrapiramidal symptoms). Moreover, the group included 36 drug-naïve first-episode patients (mean age 25.4 ± 6.4). The written consent was obtained from all the patients participating in the study, and all the procedures were approved by the local ethical committee.
Weight was measured at the 1st and 42nd day of olanzapine treatment. Weight gain was defined as X7 and X10% increase in BMI after 6 weeks of olanzapine treatment. The above thresholds were chosen to allow comparisons with other studies.
Genotyping
DNA was extracted from blood samples using the phenolchloroform technique. Genotyping was carried out by a researcher who was unaware of the clinical status of the patients.
Both polymorphisms: À759C/T (rs3813929) and À697G/C (rs518147), were analyzed from the same DNA fragment, amplified from the gene receptor sequence from À855 to À634, using the following primers described earlier: 14 forward primer 5 0 -ATCTCCACCATGGGTCTCGC-3 0 and reverse primer 5 0 -CAATCTAGCCGCTCCAAAGG-3 0 (IBB PAN, Warsaw, Poland). The PCR mix contained 60 ng of DNA, 1x PCR buffer, 2 mM of MgCl2, 200 íM of each dinucleotide triphosphate, 1 íM of each primer, 2.5 íl of 50% glycerol and 1 U of Taq polymerase (Fermentas, Vilnius, Lithuania). PCR conditions were as follows: initial denaturation at 951C for 7min., 35 cycles: 941C for 50 s, 571C for 45s, 721C for 30s and final elongation at 721C for 10 min. The product length was 252 bp.
Genotypes for both À759C/T and À697G/C polymorphisms were analyzed using restriction fragment length polymorphism, by digestion of PCR products with, respectively, 1 U of FauI restriction enzyme (New England Biolabs, Ipswich, MA, USA) and 1 U of SsiI restriction enzyme (Fermentas) overnight, according to the manufacturer's instructions. Restriction fragments were analyzed on 7% polyacrylamide gel. The patterns were as follows: À759 polymorphism: C allele 133 þ 85 þ 34 bp, T allele: 167 þ 85 bp; À697G/C polymorphism: G allele: 160 þ 54 þ 27 þ 11 or 126 þ 54 þ 34 þ 27 þ 11 bp, C allele: 160 þ 81 þ 11 or 126 þ 81 þ 34 þ 11 bp. Two different band patterns for each allele of the À697G/C polymorphism resulted from the fact that SsiI enzyme also digested the polymorphic sites of À759C/T polymorphism. The above described procedure had an additional benefit of double-checking the pattern for À759C/T found by FauI digestion.
Statistical Analysis
Distribution of genotypes was assessed using w 2 -test. Between-group comparisons were carried out using MannWhitney U and Kruskal-Wallis tests. analysis of variance was carried out to assess the influence of the alleles when a full range of BMI values was used. Stepwise regression analysis and log-linear analysis were carried out to assess the influence of baseline variables on BMI change. As two polymorphisms were analyzed, we used Bonferroni's correction for multiple testing, and P value o0.025 was considered statistically significant. All analyses were carried out using Statistica 7.1 software (Statsoft, Tulsa, OK, USA).
